What is PHAT stock price today?

PHAT (Phathom Pharmaceuticals Inc) stock is trading at $12.61 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is PHAT stock going up or down today?

PHAT stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy PHAT stock now?

The decision to buy PHAT depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is PHAT a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for PHAT based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is PHAT stock overvalued or undervalued?

Use our DCF valuation calculator to determine if PHAT is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is PHAT's P/E ratio?

P/E ratio data for PHAT will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is PHAT's market cap?

PHAT (Phathom Pharmaceuticals Inc) has a market capitalization of $1.02 billion, making it a small-cap stock.

What is PHAT's price to book ratio?

PHAT trades at a price-to-book (P/B) ratio of 25.37, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does PHAT pay dividends?

PHAT does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is PHAT's dividend yield?

PHAT does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is PHAT stock a good long-term investment?

PHAT's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is PHAT's revenue growth rate?

PHAT has shown revenue growth of 0.9% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

PHAT is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in PHAT?

Key risks for PHAT include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does PHAT compare to its competitors?

Compare PHAT to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize PHAT's performance and positioning.

What is PHAT's stock price target for 2026?

Our AI model provides price targets for PHAT based on fundamental analysis: Bull case $16.39 (+30%), Base case $14.50 (+15%), Bear case $11.35 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about PHAT?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for PHAT. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is PHAT's next earnings report?

PHAT reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

PHAT - Phathom Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$12.61

$-0.18 (-1.41%)

About Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

PHAT Key Statistics

Market Cap

$1.02B

P/B Ratio

25.37

EPS

$-3.03

Revenue Growth

+0.9%

Profit Margin

-1.3%

Employees

371

How PHAT Compares to Peers

PHAT has the fastest revenue growth among competitors

PHAT is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
PHAT(This stock)	$1.02B	N/A	1%	-1.3%	-
AMGNAmgen Inc	$187.71B	24.5	0%	0.2%	vs AMGN
GILDGilead Sciences	$173.48B	20.6	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.35B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.71B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$25.83B	20.0	-0%	0.1%	vs BIIB

Phathom Pharmaceuticals Inc Company Information

Headquarters: New Jersey; U.S.A
Website: www.phathompharma.com
Sector: Health Care
Industry: Biotechnology

PHAT - Phathom Pharmaceuticals Inc

About Phathom Pharmaceuticals Inc

PHAT Key Statistics

How PHAT Compares to Peers

Phathom Pharmaceuticals Inc Company Information

PHAT Lician Score

PHAT Financial Snowflake

Upcoming Events for PHAT